PAVmed Analyst Price Targets - Benzinga

PAVmed Inc

PAVMNASDAQ

Trade with Public

Trade with Public

$1.95

-0.02-1.02%

Últ. Act.: Oct 30, 5:58 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

© 2026 Benzinga | All Rights Reserved

PAVmed Analyst Price Targets - Benzinga

PAVmed Analyst Price Targets

Wall Street analyst price targets and consensus rating for PAVmed (PAVM).

Price Target Range — 6 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$57Upside to Avg. PT+2614.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$56→$57
Jun 8, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$65→$56
Apr 9, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$510→$65
Dec 10, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$600→$510
Oct 6, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$570→$600
Jun 6, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$585→$570
Apr 21, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$570→$585
Dec 9, 2024	Ascendiant Capital	Edward Woo	PT Cut	Buy	$630→$570
Sep 10, 2024	Ascendiant Capital	Edward Woo	PT Cut	Buy	$660→$630

Analyst Ratings News

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $57

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $56

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $65 to $56.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $17

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $20 to $17.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $20

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $19 to $20.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $19

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $19.5 to $19.

Benzinga Newsdesk